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ABSTRACT
Background: Currently there is no vaccine available in use against any form of
leishmaniases worldwide.
Objective: To assess potential of a live-attenuated Leishmania major promastigates, for
protection against a challenge infection with L. major in BALB/c mice.
Design. A laboratory based study.
Setting: Study was carried out at Centre for Biotechnology Research and Development,
Kenya Medical Research Institute, Nairobi.
Results. The greatest protection against challenge with L. major was seen in mice
immunised with live parasites (P<0.001) compared to vaccinations with heat killed or
soluble antigens. In general, immunised mice produced high level of antileishmanial
antibodies and T cell stimulation to their respective antigens.
Conclusions: Our live-attenuated parasites produced by serial sub-culture of L. major
parasites 118 times showed the capacity to induce appropriate cell-mediated immune
responses and protection against L. major infection in BALB/c mice. Data also suggests
that these parasites do not revert to virulence when injected subcutaneously in mice.
INTRODUCTION
Leishmania is a genus of flagellated protozoan
parasites that cause a wide range of human diseases
collectively known as leishmaniases. Leishmaniases are
worldwide in distribution, accounting for 20 million
new cases per year with 1.5 persons at risk (1). The
disease is prevalent in many tropical and sub-tropical
regions of the world, where it is transmitted via the
bite of an infected sand fly. Currently, disease control
strategies rely on chemotherapy to alleviate the disease
and on vector suppression and personal protection to
reduce transmission.
Leishmania major causes cutaneous leishmaniasis
in the old World and produces wet skin ulcers, which
leave unsightly scars on healing (2). L. major infection
in Kenya is zoonotic with a wide variety of natural
hosts being wild animals, which are little affected by
the presence of the parasites. Man is almost always an
accidental host when he intrudes into the natural habitat
of the wild hosts and vector sand flies (3).The parasite
is transmitted by Phlebotomius duboscqi (4) and the
parasites have been isolated from various rodents such
as Tatera robusta, Xerus rutilus (5,6), Mastomys
natalensis, Taterillus emini, Aethomys Kaiseri (7) and
a vervet monkey Cercopithecus aethiops (8). The
disease is endemic in Baringo and West Pokot Districts,
Rift Valley Province, Kenya (7,9).
Treatment of leishmaniases generally involves the
use of high doses of pentavalent antimonial compounds,
sodium stibogluconate (Pentostam) and meglumine
antimonate (Glucantine®) (10). However, the cost, duration
of administration, toxic nature of antimonial compounds
and the tendency for the disease to relapse after an initial
successive regime of chemotherapy underscore the need
for an effective, safe and a cheap vaccine to be used as
an intergrated approach to control leishmaniases.
Previous studies with L. tropica and L. donovani
showed that prolonged in vitro  cultivation of
promastigotes reduced the infectivity and the virulence
of these parasites (11,12). The efficacy of such
promastigotes (attenuated by prolonged in vitro
cultivation) to induce protective immunity in the host
against the Leishmania infections has not been examined.
This study sought to evaluate L. major promastigotes that
have been serially sub-cultured one hundred and eighteen
times (118°) for vaccine development in leishmaniasis.
MATERIALS AND METHODS
Mice. BALB/c mice aged six to eight week were
obtained and maintained in the KEMRI animal house facility.
These experiments complied with all relevant institutional
policies. Leishmania promastigote cultures and preparation of
antigens. Virulent L. major parasite (strain IDUB/KE/83=NLB
144) was originally isolated from a female P. duboscqi,
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collected near Marigat, Baringo District, Rift valley province
of Kenya and has since been maintained in BALB/c mice
(4). Parasites were aspirated from infected footpad lesions of
BALB/c mice and cultured in NNN/Schneider's Drosophila
insect medium supplemented with 20% foetal bovine serum
(FBS), 250U/ml penicillin, 250µg/ml streptomycin and 500g/
5ml flourocytocine arobinoside at 25°C. The parasites were
grown and harvested at metacyclic promastigote stage. Parasites
serially sub-cultured one hundred and eighteen times (118°)
were used as live-attenuated parasites. Heat killed antigens
were prepared by heat killing of whole promastigotes at 60°C
in a water bath for ten minutes. Soluble antigens (SLA) were
prepared by subjecting the stationery phase promastigote to
several cycles of freeze thawing and finally centrifuged at
10,000 rpm for 15 minutes at 4°C. The supernatant was
reconstituted in normal saline. Protein concentrations in
antigens were estimated using Lowry technique (13) and then
stored at -20°C before use.
Immunisation protocol: Four groups each containing thirty
BALB/c mice matched by age and sex were immunised
intravenously through the tail vein (14). The first group of mice
was immunised with 1 x 106 live-attenuated metacyclic parasites
in 50µl normal saline. The second group was immunised with
1 x 106 heat killed whole parasites in 50µl normal saline. The
third group was immunised with 50µg of SLA in 50µl normal
saline. The final group immunised with 50µl normal saline
formed the controls. All mice were boosted with the same dose
of antigen at seven days interval for four weeks.
Determination of humoral immune responses against L.
major-derived antigens: Twenty mice from each group were bled
one week after the third booster by tail snipping method as
previously described (14). Briefly, two haematocrit tubes full
of blood were collected from each mouse and blotted onto two
opposite spots of a filter paper. Filter papers were dried and
stored at 4°C until spots containing serum were cut out and put
in an elution tube containing 5% Tween 20 bovine albumin in
saline containing phosphate 0.05% Tween 20 (PBST) as a
diluent. Enzyme linked immunosorbent assay (ELISA) was used
to assay the antibody level in the sera as previously described
(14). Rabbit anti-mouse Immunoglobin G (IgG) peroxidase
conjugate and 2.2'-azinodi [3-ethyl-benzthiozoline sulfate] (ABTS)
peroxidase substrate were used. Optical density was read using
an ELISA reader with a 492nm filter.
Lymphocyte proliferation assays: Lymphocytes were
obtained from mice spleens as previously described (15).
Spleens from immunised animals or control groups were
aseptically crushed on a wire mesh using a syringe plunger
and mononuclear cells were separate using Ficoll gradients.
Cell viability was determined by trypan blue exclusion
principle. 3 x 106 cells per ml were stimulated in vitro (37°C
in 5% CO2) with 50µg SLA per ml or medium alone. After
72 hours, the cultures were pulsed with 0.5µCi [3H] thymidine
for 18 hours and cell proliferation evaluated by liquid
scintillation counting.
Determination of delayed type hypersensitivity (DTH):
Both immunised and control mice were injected in the left
hind footpad with 25µg of the SLA (16). This amount of
antigen had been determined in preliminary studies to be
suitable for DTH elicitation. The induration was expressed
as the difference between the thicknesses measured before,
24 or 48 hours after eliciting the injection. The measurements
were made using a vernier caliper. Indurations above 0.5mm
were recorded as positive (16). Control animals were not
tested for DTH responses using the molecule to avoid any
sensitisation before challenge infection.
Macrophage activation assay: To determine the parasiticidal
efficiency of peritoneal macrophages from immunised mice,
these cells were harvested from both immunised mice as
previously described (17). Briefly, three weeks after the third
booster, peritoneal macrophages from both immunised and naive
mice were collected by lavage of the unstimulated peritoneal
cavity with RPMI 1640 medium buffered with 25mM HEPES.
After three washes in PBS, cells were plated on culture flasks
containing buffered RPMI 1640 medium, supplemented with
10% FBS plus penicillin/streptomycin and incubated in vitro at
37°C in 5% CO2 95% air. After two hours of incubation, non-
adhering cells were removed by rinsing with cold medium while
he adhering cells were cultured for f urty hours to allow for
adequate spreading. After three rinses and renewal of the RPMI
1640 medium-FBS, the cultured cells were exposed to virulent
L. major promastigotes and incubated at 37°C in 5% CO2 95%
air. After periods of infection at four, twenty four and fourty
eight hours, the macrophage monolayers were washed, fixed for
five minutes in absolute ethanol and stained for 30 minutes with
10% Giemsa. The level of infection in these cultures was
calculated by counting macrophages in random microscopic
fields in two separate culture dishes and expressing the number
of infected macrophages as a percentage of the total number
of macrophages counted.
Infection of mice and determination of parasite burdens
in the spleens and liver: One week after the third booster, all
the immunised and control animals were infected with 106
virulent promastigotes in the footpad. Lesion development was
monitored by measuring both infected and uninfected footpads
once a week using a vernier caliper and the difference between
the thicknesses of the two footpads was reported as the lesion
size. At 14 weeks post-infection, all mice were killed and their
liver and spleens removed. Pieces of these organs were cultured
in NNN overlaid in complete Schneider's medium to determine
in the presence of parasites. Impression smears were also made
from liver and spleen and Giemsa stained. The number of
amastigotes per 1000 organ cell nuclei were counted and the
number of parasites (X) in organs was derived from the formula
X= LDU/1000 multiplied by the weight of the organ (in mg)
and a constant 2x105 (18).
Determination of persistence of the live-attenuated
parasites: Two separate groups of mice were infected with
either live-attenuated L. major or virulent parasites 106
stationary phase promastigotes subcutaneously in the footpad.
The presence of these parasites was monitored by obtaining
aspirates from the infected site six, twelve and twenty four
hours post-infection. Some of the material from the aspirates
was cultured and examined daily for the presence of
promastigotes. Impression slides from aspirates were Giemsa-
stained and examined for amastigotes. The same procedure
was repeated seven and thirty days post-infection respectively.
RESULTS
Humoral responses against Leishmania-derived
antigens: Results showed that mice immunised by
intravenous injection with various antigens derived
from the metacyclic L. major promastigotes produced
substantial amount of antibodies as shown in Table
1. However, vaccinations with live-attenuated parasites
induced the highest production of antibody titers
compared to vaccinations with soluble antigens or heat
killed whole parasites (P<0.05).
April 2005 EAST AFRICAN MEDICAL JOURNAL 195
Table 1
Mean antibody responses to L. major soluble antigens following immunisation with the respective antigens
Immunising antigen                                    Mean optical densities (OD ± S.E)
Live-attenuated parasites 0.283 ± 0.004
Heat killed whole parasites 0.198 ± 0.085
Soluble antigens 0.223 ± 0.040
Controls 0.000 ± 0.000
Cell-mediated responses in immunised mice.
Cellular immunity against the various Leishmania
antigens was assessed in vaccinated animals by delayed
type hypersensitivity (DTH) and recall proliferative
responses to soluble antigen (SLA) in immunised
animals. Results showed that all immunised mice
showed DTH responses in recognition to soluble
leishmanial antigen 24 hours post challenge (Table 2).
However, vaccinations with live-attenuated parasites
showed prolonged and sustained DTH responses 48
hours before challenge (Table 2).
Table 2
Delayed-type-hypersensitivity responses in BALB/c mice following a triple immunisation with
various leishmanial antigens
Immunising antigen Mean skin induration in MM ± S.E.
24 Hours 48 Hours
Live-attenuated parasites 1.30 ± 0.08 1.00 ± 0.09
Heat killed whole parasites 1.20 ± 0.01 0.00 ± 0.00
Soluble antigens 1.00 ± 0.09 0.00 ± 0.00
Controls 0.00 ± 10.00 0.00 ± 0.00
All the vaccinated mice also exhibited proliferative T-
cell responses to SLA, an indication of immunological
memory after immunisation. Animals vaccinated with
soluble antigen revealed the highest T-cell proliferation
(Stimulation index = 4.8) followed by those vaccinated
with heat killed whole parasite antigen (Sl = 3.8)
whereas the mice immunised with live-attenuated
parasites induced the least (Sl = 3.0). However, these
responses were not statistically significant (Figure I ).
Figure 1
Proliferative response to L. major-derived SLA antigen
by mononuclear cells from BALB/c mice following
immunisation with various leishmanial antigens
Parasiticidal activities of peritoneal macrophages
from immunised mice. The peritoneal macrophages from
the various immunisation groups were shown to be
capable of eliminating virulent L. major promastigotes
which were introduced into them, but they differed in
their ability to eliminate the parasites depending on the
type of antigen that was used in immunising the animals.
After 24 hours of infection, only 10% of the resident
peritoneal macrophages from mice immunised with live
attenuated parasites were still parasitised compared to
13%, 10% and 24% from the heat-killed, soluble antigen
and un-immunised mice, respectively. After 48 hours of
infection, the number of infected cells reduced drastically
with those from mice immunised with live-attenuated
parasites promastigotes being 2%, 8% from mice
immunised with heat killed promastigotes, 4% from mice
immunised with soluble antigens and control group still
had 20% of its cells infected (Table 3).
Table 3
Vaccinating 24 hours Duration in hours 72 hours
antigens (%) post infection (%)
48 hours (%)
Live-attenuated 10 2 0
Heat killed whole
  parasites 13 8 0
Soluble antigens 10 8 0
Controls 24 20 6
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Lesion development in BALB/c mice following
challenge with virulent L. major promastigotes: Figure
2 shows the mean lesion sizes in mice from each group
following challenge with virulent L. major parasites and
which were monitored for a period of 14 weeks. Results
showed that mice immunised with live-attenuated
parasites developed significantly smaller lesion sizes
compared to those immunised with SLA or heat killed
promastigotes (P<0.001). Lesion sizes in mice
immunised with animals immunised with SLA and
heat-killed whole parasite antigen did not vary
statistically from those of the controls (P>0.05).
Figure 2
Mean lesion size of BALB/c previously vaccinated with
various antigens and later challenged with virulent
L. major promastigotes
Table 4
Mean weights (grams ±S.E.) of liver and spleen of
BALB/c mice at 14 weeks post-infection
Vaccination groups              Infected organ
Liver Spleen
Live-attenuated parasites 1.08 ± 0.046 0.43 ± 0.024
Heat killed whole 1.18 ± 0.079 0.45 ± 0.020
parasite antigen
Soluble antigens 1.19 ± 0.090 0.46 ± 0.042
Controls 1.33 ± 0.056 0.48 ± 0.030
Parasitaemia levels in the liver and spleen biopsies.
Cultures from liver and spleen from mice immunised
with SLA and heat killed parasites were shown to be
positive for parasites. Those from mice immunised with
live-attenuated parasites were shown to be negative.
However, the mean weight and sizes of spleens or liver
from mice immunised with various antigens did not
differ significantly with those of the controls (P>0.5).
Persistence of the live-attenuated parasites at the
site of inoculation in BALB/c mice: Live-attenuated
parasites inoculated in mice were detected from infection
site 48 hours post-infection. This was supported from
both culture and thin smear results that were all
negative. However, mice infected with virulent
L. major parasites all had parasites in the infection site.
DISCUSSION
To date there is no vaccine against Leishmania in
routine use anywhere in the world (19). The only
vaccination strategy used so far in humans with proven
success against cutaneous leishmaniasis has required
controlled induction of disease with virulent parasites
(20). However, this practice has been abandoned because
some individuals did not cure these initial purposeful
infections (21,22).
The primary focus in modern vaccine research has
been on the development of killed whole or fractionated
antigen preparations and more recently on recombinant
proteins, attenuated live parasites or DNA vaccines
(19). In the present study we investigated the ability
of live-attenuated, heat killed whole promastigotes and
SLA to protect against a challenge infection with L.
major in BALB/c mice. Results showed that BALB/
c mice immunised with live-attenuated parasites
produced significantly higher humoral and cell-mediated
immune responses compared to vaccinations with heat
killed or SLA (P<0.05).
BALB/c mice infected with L. major parasites
develop a progressive infection involving large ulcerating
lesions in the infected footpad, loss of foot due to
necrosis, metastastic spread of the parasites to secondary
cutaneous sites as well as the viscera, and eventual
death of the animals (23). Results showed that mice
immunised with live-attenuated parasites developed
significantly smaller lesion sizes compared to those
immunised with SLA or heat killed promastigotes
(P<0.001). Lesion sizes in mice immunised with SLA
and heat-killed whole parasite antigen did not vary
statistically from those of the controls (P>0.05). No
parasites were also detected in viscera from mice
immunised with live-attenuated parasites while those
immunised with SLA or heat-killed parasites exhibited
visceralisation and eventually died of infections with
L.major.
Previous studies have shown that BALB/c mice
injected with avirulent or with irradiated parasites were
also protected from infection (24,25). In mouse, L.
major parasites lacking the gene encoding the enzyme
dihydrofolate reductase-thymidylate synthetase (DHFR-
TS) induced protection against infection with either L.
major or L. amazonensis (26, 27). An attenuated line
of L. mexicana was also used successfully to protect
against homologous infection (28, 29).Taken together,
these data strongly supported prophylactic vaccination
with attenuated organisms as a useful approach to
human vaccine development. Recent advances to
manipulate the Leishmania genome by introducing or
eliminating genes have the potential to make live-
attenuated vaccines much more feasible.
The use of attenuated organisms is very attractive
because they are the closest mimic to the natural course
of infection and may therefore lead to similar immune
responses. Moreover, because of the small load of
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antigen delivered by the transient challenge, the immune
responses may be skewed even more towards a
ThI-type than in natural infections (30,31). Such
immunisation will also deliver many more parasite
antigens than the limited number possible with
recombinant or sub-unit antigens (25).
Our live-attenuated parasites produced by serial
sub-culture of L. major parasites 118 times have shown
the capacity to induce appropriate cell-mediated immune
responses and protection against L. major infection in
BALB/c mice. Our data also suggests that these
parasites do not revert to virulence when injected
subcutaneously in mice. Our laboratory is now in the
process of analysing their genetic profile for future
vaccine development in leishmaniasis.
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ABSTRACT
Objectives: To document trends in parameters of nutrition in south-western Nigerian
school girls in comparison with earlier reports and provide baseline data for future
comparison.
Design: A cross-sectional study.
Setting: Fifteen secondary schools from the five local governments in Ibadan, Oyo State
in south-western Nigeria.
Subjects: One thousand six hundred and seventy five apparently healthy female students
aged between nine and twenty three years.
Results: One thousand six hundred and seventy three questionnaires were analysed. The
mean age, mean height and mean body weight were 15.45 years ± 2.06 (SD), 154.98cm
± 8.4(SD) and 46.09kg ± 8.8 (SD) respectively. The mean body fat was 11.12kg ± 4.6
(SD); mean lean body mass (LBM) was 34.96kg ± 4.6 (SD); mean total body water
(TBW) was 25.17L ± 3.3 (SD) and the mean body index (BMI) was 19.07kg/m2 ±2.7
(SD). Girls from upper socio-economic background had significantly higher values of
anthropometric measurements and body composition for each age than lower socio-
economic class girls. Compared with their peers from another Nigerian city investigated
two decades ago, girls in this study were significantly lighter and shorter.
Conclusion: The study revealed a decline in nutritional parameters among adolescents.
The implications of these findings for the reproductive health of Nigerian women are
discussed. Serial studies to monitor trends in adolescents are recommended.
INTRODUCTION
Nutritional status is an index of health and well-
being at both the individual and population levels.
Studies assessing indices of nutrition have been sparse
in Nigerian school girls. Fewer studies still have
evaluated body composition in Nigerian girls. Available
reports however suggest lower values of anthropometric
measurements in developing countries compared with
the developed world, and consequently a poorer level
of nutrition (1).
Nutritional assessments need to be updated frequently
in view of the dynamic nature of the interactive factors.
Prominent among these factors is the role of the national
economy. The economies of many developing nations
have been in recession with predictably deleterious effects
on their populations; a decrease in body weight and body
fat has been shown to be associated with inadequate food
and energy supplies on a national level (2). It is against
this background that we set out to document some
parameters of nutrition in school girls with a view to
evaluating the trend in comparison with earlier reports and
provide baseline data for future comparison.
MATERIALS AND METHODS
This cross-sectional study involved 1675 apparently
healthy secondary school students randomly selected from 15
public secondary schools from the five local governments
within Ibadan city. Selection was done by multi-stage sampling.
In each local government, three schools were randomly
selected. In the selected schools, one arm in each class
(among Junior Secondary School classes 1-3 and Senior
Secondary School classes 1-3) was then selected and twenty
girls were randomly selected to participate in the study.
Permission for the study was obtained from the
supervising Ministry of Education. In each school, the school
administration gave its consent and in every selected class,
the Tutor explained the nature of the study to all students.
The instrument was a pre-tested semi-structured questionnaire,
which sought to obtain the date of birth, the mother's level
of education and the father's occupation. The social class of
the students was derived from the combination of the mother's
level of education and the father's occupation as described
by Olusanya et al (3).
The height (cm) was measured with the girls barefoot
and in light-clothing using a standardised metre rule. The
body weight (kg) with the girls barefoot and in light-clothing
